These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2444986)

  • 1. The intrainfusion rebound platelet activation during continuous prostaglandin I2 infusion occurs at the receptor level.
    Sinzinger H; Steurer G; Fitscha P; Kraupp O
    Prog Clin Biol Res; 1987; 242():19-23. PubMed ID: 2444986
    [No Abstract]   [Full Text] [Related]  

  • 2. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
    Steurer G; Fitscha P; Sinzinger H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD).
    Fitscha P; Tiso B; Krais T; Sinzinger H
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():450-4. PubMed ID: 2444079
    [No Abstract]   [Full Text] [Related]  

  • 4. Heterologous desensitization of platelet adenosine (A2) responses by iloprost.
    MacDermot J; Wilkins AJ; Edwards RJ
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():479-81. PubMed ID: 2444081
    [No Abstract]   [Full Text] [Related]  

  • 5. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
    Jaschonek K; Renn W; Weisenberger H
    Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
    [No Abstract]   [Full Text] [Related]  

  • 6. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
    Fitscha P; Tiso B; Sinzinger H
    Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
    [No Abstract]   [Full Text] [Related]  

  • 7. Augmented platelet-endothelial adhesion induced by PGI2 receptor desensitization.
    Darius H; Binz C; Veit K; Fisch A
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():427-9. PubMed ID: 7537435
    [No Abstract]   [Full Text] [Related]  

  • 8. The intrainfusion platelet rebound during and following PGE1-infusion is faster and more intensive than that with PGI2.
    Sinzinger H; Reiter S
    Prostaglandins Leukot Med; 1984 Mar; 13(3):281-8. PubMed ID: 6585847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of selective [3H]iloprost binding sites on human platelet membranes.
    Steurer G; Jankovic B; Ettl K; Schernthaner G
    Prog Clin Biol Res; 1987; 242():25-34. PubMed ID: 2444987
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of prostaglandin I2 derivative infusion during experimental cardiopulmonary bypass].
    Matsukura H; Takeda H; Uzawa S; Sakai K; Kawakami T; Tanabe T
    Nihon Kyobu Geka Gakkai Zasshi; 1983 Jun; 31(6):871-5. PubMed ID: 6352833
    [No Abstract]   [Full Text] [Related]  

  • 11. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
    J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
    Pedvis LG; Wong T; Frojmovic MM
    Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets.
    Paul S; Kurunwune B; Biaggioni I
    J Pharmacol Exp Ther; 1993 Nov; 267(2):838-43. PubMed ID: 8246157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of platelet [3H] iloprost binding by cholesterol, dibucaine and pentoxifylline.
    Jaschonek K; Funck M; Muller CP; Schmidt H
    Prog Clin Biol Res; 1989; 301():321-5. PubMed ID: 2477853
    [No Abstract]   [Full Text] [Related]  

  • 15. Human prostacyclin receptor: cloning and co-expression with EP3 prostaglandin receptor.
    Ortiz-Vega S; Ashby B
    Adv Exp Med Biol; 1997; 433():235-8. PubMed ID: 9561143
    [No Abstract]   [Full Text] [Related]  

  • 16. Potent inhibition of PAF-stimulated human platelets and polymorphonuclear leukocytes by the PGE1 analog OP-1206.
    Hecker G; König E; Ney P; Schrör K
    Prog Clin Biol Res; 1987; 242():317-22. PubMed ID: 2444988
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility.
    Kerins DM; Murray R; FitzGerald GA
    Prog Hemost Thromb; 1991; 10():307-37. PubMed ID: 1848945
    [No Abstract]   [Full Text] [Related]  

  • 18. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of PGD2, PGE1, and PGI2-analogues on PGDF-release and aggregation of human gelfiltered platelets.
    Stürzebecher S; Nieuweboer B; Matthes S; Schillinger E
    Prog Clin Biol Res; 1989; 301():365-9. PubMed ID: 2477855
    [No Abstract]   [Full Text] [Related]  

  • 20. Receptors and mechanisms of action of prostacyclin in preserving non-mucosal cell integrity.
    Nicosia S; Oliva D; Paoletti R
    Gastroenterol Clin Biol; 1985; 9(12 Pt 2):33-6. PubMed ID: 2422088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.